Perrigo Company plc Equity Method Investment, Realized Gain (Loss) on Disposal
Perrigo Company plc (PRGO) reported Equity Method Investment, Realized Gain (Loss) on Disposal of -$2.80 million for the 12-month period ending 2014-06-28, per its 10-K filed 2017-05-22.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal · last filed 2017-05-22
- Perrigo Company plc equity method investment, realized gain (loss) on disposal for fiscal 2014 was -$2.80M.
| Period end | Equity Method Investment, Realized Gain (Loss) on Disposal 12 month |
|---|---|
| 2014-06-28 | -$2.80M 10-K · filed 2017-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |